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Abstract 
The paper presents the reaction of companies that have been making the 
largest outlays on R&D in a global scale to the current economic crisis. The 
analysis paid special attention to what extent R&D investments had been 
affected in comparison with net sales and profits and how R&D investments 
were affected across industries and regions. 
The analysed enterprises reduced their net sales and profits to a greater 
extent than outlays on research and development, which confirms an anti-
cyclical character of R&D activity in leading innovative enterprises. It has to be 
noted that in an analysed sample some companies significantly decreased 
outlays on R&D, however, there were some that increased these outlays in spite 
of worsening economic performance. 
Among investigated sectors the one that proved to be the most crisis-
resistant was the pharmaceuticals & biotechnology sector - classified as high 
technology, whereas the most crisis-prone one was the automotive sector.  
Nonetheless, the thesis that high tech industries are more crisis-resistant 
cannot be substantiated – outlays on research and development in the following 
sectors: computer production, office equipment, semiconductors, 
telecommunications equipment (technology hardware & equipment) - classified 
as high technology in 2009 were reduced in relation to year 2008. 
In an analysed group of enterprises the smallest “resistance” to crisis 
was observed in American companies. The enterprises from the EU also reduced 
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research and development expenditures but the pace of a fall in these 
expenditures was smaller than in the case of American companies.  
1. Introduction 
The reduction of research and development expenditures can be  
a corporate reaction to an economic crisis - in case of business entities it is 
referred to as a “cyclical” one. The anti-cyclical character of R&D activities, 
however, means that in the time of crisis enterprises increase investments in 
research and development, thanks to which they can improve their competitive 
position in the market, even during the time of economic slowdown. 
The aim of this paper is to examine the impact of crisis (2008-2009) on 
R&D activity of leading innovative enterprises. The analysis pays special 
attention to what extent R&D investments were affected in comparison with net 
sales and profits and how R&D investments were affected across industries and 
regions.  
The introduction to the analysis is the presentation of various research and 
development strategies undertaken by enterprises as a reaction to an economic 
crisis. Later on, the changes of R&D expenditure in leading innovative 
companies in the period between 2008-2009 have been examined [enterprise 
ranking based on European Commission (2010), The 2010 EU Industrial R&D 
Investment Scoreboard, Luxemburg]. The cited report presents a group of 
leading innovative enterprises i.e. those whose R&D budget in 2009 exceeded 
the annual level of 28 million Euros. The criterion was met by 1400 companies 
(400 from the EU, 1000 from outside the EU). 
2. Corporate Research and Development Strategies in the Time  
of Economic Crisis 
The assessment of the impact of economic crisis on the dynamism of 
corporate research and development investment has evoked a lot of controversy 
in the economic literature.  
Research and development activity is treated similarly to other functional 
segments (activities) of enterprises which take part in the process of creating 
value, i.e. value chain (Rymarczyk 2004, pp. 90–91). Thus companies can 
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decrease R&D expenditures in order to reduce costs, which defines this activity 
as cyclical in the time of crisis. As M. Cincera, C. Cozza, A. Tuebke, P. Voigt 
claim: „Implementation of new ideas can be postponed by enterprises to the 
times of economic recovery” (Cincera, Cozza, Tuebke, Voigt 2010, p. 3).  
The factor that notably limits research and development expenditure is  
a difficult access to external sources of financing in the conditions of financial 
crisis. Enterprises that suffer from a fall of demand for their products and lower 
profits simultaneously lose the ability to apply for credit to finance R&D 
activities. Moreover, the reluctance of banks to lend their financial surpluses to 
other financial institutions limits their lending. In the economic literature it is 
emphasized that R&D expenditure has a “cyclical” character in case of 
enterprises facing credit crunch (Aghion, Askenazy, Berman, Cette, Eymard 
2008, p. 2). 
S. Martin, P. Valbonesi (Galli, Pelkmans 2000, p. 191) draw attention to  
a high level of risk accompanying R&D activity, which results in 
“underinvestment” in research and development in market system. A company 
that invents a new technology tries to protect it as long as possible from being 
publicized and used by other producers in order to benefit from their 
innovativeness for a long time (Górniewicz, Siemiątkowski 2006, p. 120). The 
process of using the knowledge by followers who do not incur expenditure on 
R&D activity but take advantage of results of other enterprises is inevitable. The 
fact that the knowledge is used by imitators diminishes the profits of innovators. 
The conflict between the public character of knowledge and profits made by 
innovator-enterprise is defined as a problem of appropriation. The risk of 
appropriating innovator’s profits undoubtedly discourages research and 
development activities. In the time of crisis projects like that are highly 
adventurous (as it was already stated all R&D activities are) and often are 
“suspended”, which supports treating R&D expenditures as cyclical.  
However, reducing R&D expenditures can in future imply losing  
a competitive fight with companies that in the time of crisis did not decide to 
decrease this type of investments (Cincera, Cozza, Tuebke, Voight 2010, p. 4). 
Describing research and development activity as a key factor of 
competitive advantage is a starting point for further analysis of anti-cyclical 
character of research and development expenditures. Thanks to increased 
expenditures on R&D companies not only improve their competitive position in 
a short time but they also gain a long-term competitive ability.  
The negative impact of crisis on a company profitability can force it to 
undertake some actions stimulating growth of productivity (Voight, Moncada- 
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Paterno-Castello 2009, p. 5). So-called models of research and development 
activities (referred to as endogenous models of economic growth) by means of 
production functions enable to analyse the impact of R&D activity on 
productivity1. The characteristics of these theories, contrary to traditional 
endogenous growth models, is the occurrence of R&D sector (as a separate 
sector of economy) as well as modelling of technologies. The research proves 
that company innovation, described as their ability to adapt new solutions is  
a very important determinant of productivity growth (Bogliacino, Pianta 2009,  
p. 3). 
According to the J.Schumpeter’s concept of “creative destruction” crisis 
brings new opportunities for an enterprise including reorganization and increase 
of advancement level of R&D activity (Burzyński 2010, p. 42). A disappearing 
profitability rate forces business entities to implement new techniques of 
production. Companies that will not implement a proper reorganization of 
research and development activity as a reaction to crisis can be susceptible to 
bankruptcy. 
Strategic and long-term character of research and development 
investments results in their “resistance” to crisis. Financial constraints being the 
effect of crisis to a greater extent influence decisions concerning the launch of 
new research and development projects (crisis can result in the abandonment of 
new research and development ventures), whereas the projects in the course of 
realization are influenced to a lesser extent. The abandonment of already 
commenced projects, advanced in the course of implementation generates so-
called “sunk” costs (Cincera, op. cit., p. 3).  
It must be stressed that an enterprise reaction to crisis to a great extent 
depends on the specificity of a given sector/branch. Enterprises belonging to 
high-tech industries find themselves in a better economic position than 
enterprises from other sectors (Leadbeater, Meadway 2008, p. 12). A. Stephen 
observes that enterprises from high-tech industries are more resistant to  
a business cycle than those belonging to sectors defined as medium-low-tech 
industries, so the reaction of the first group of enterprises to crisis can be 
described as anti-cyclical (Stephan 2004). 
A crucial factor that determines the change of research and development 
expenditures as a reaction to crisis is also the size of a company characterized by 
the level of employment or annual turnover. Large enterprises i.e. those who  
                                                 
1
 More on so-called R&D models see Nowak (2007, s. 283). 
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possess relatively big budgets for research and development projects are more 
resistant to crisis than small and medium-sized enterprises. A pro-cyclical 
character of R&D expenditures in SME’s sector is described by M. Cincera,  
C. Cozza, A. Tuebke, P. Voigt (Cincera M., Cozza C, Tuebke A., Voigt P. p. 5). 
3. Changes in research and development expenditures of innovative 
enterprises as a reaction to crisis – overall analysis 
1400 leading innovative enterprises allocated 402,2 bn Euros to research 
and development in 2009, which was only 1.9% less than in the previous year2. 
The crisis to a great extent reduced net sales (by 10.1 %) as well as profits (by 
21%) of analysed companies, which may imply that investments in research and 
development are relatively resistant to recession. It is also confirmed by priority 
meaning of research and development activity for enterprises that incur the 
biggest expenditures on R&D on a global scale. 
The global leader of R&D expenditures is still a Japanese company, 
Toyota (compare graph 1) although in 2009 the company reduced R&D 
expenditures in relation to year 2008 by 5.7% (compare Tab.1). Toyota kept its 
number 1 position in the ranking in spite of a significant decrease of net sales 
value and operating profit (European Commission 2010, p. 23). 
                                                 
2
 Analysis of research and development activity of innovative enterprises on the basis of the 
European Commission (The 2010), EU Industrial R&D Investment Scoreboard, Luxemburg. 
Group of 1400 leading innovative enterprises (400 from the EU, 1400 from outside the EU) 
consists of enterprises whose budgets for R&D exceed annually 28 m Euros. 
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Figure 1. Ranking of the world's top 50 R&D companies by their total R&D investment  
Source: European Commission (2010). 
1. Toyota Motor, Japan
2. Roche, Switzerland
3. Microsoft, USA
4. Volkswagen, Germany
5. Pfizer, USA
6. Novartis, Switzerland
7. Nokia, Finland
8. Johnson&Johnson, USA 
9. Sanofi-Aventis, France
10. Samsung, Electronics,South Korea
11. Siemens, Germany
12. General Motors, USA 
13. Honda Motor, Japan
14. Daimler, Germany
15. GlaxoSmithKline, UK
16. Merck, USA 
17. Intel, USA 
18. Panasonic, Japan
19. Sony, Japan
20. Cisco Systems, USA 
21. Robert Bosch, Germany
22. IBM, USA 
23. Ford Motor, USA 
24. Nissan Motor, Japan
25. Takeda Pharmaceutical, Japan
26. Hitachi, Japan
27. AstraZeneca, UK
28. Eli Lilly, USA 
29. Bayer, Germany
30. EADS, The Netherlands
31. Toshiba, Japan
32. Alcatel-Lucent, France
33. NEC, Japan
34. Bristol-Mayers Squibb, USA 
35. BMV, Germany
36. Boeing, USA 
37. Ericsson, Sweden
38. General Electric, USA 
39. Peugeot (PSA), France
40. Canon, Japan
41. Oracle, USA
42. Denso, Japan
43. Motorola, USA 
44. Boehringer Ingelheim, Germany
45. NTT, Japan
46. Amgen, USA 
47. Google, USA 
48.Hewlett-Packard, USA 
49. Finmeccanica, Italy
50. Abbott Laboratories, USA 
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Table 1. Characterization of the world's top 50 R&D companies (2009) 
Compan R&D Investment 
(change 09/08, %) 
R&D/Net Sales ratio 
(2009, %) 
Operating Profit 
(% of Net Sales, 
2009) 
1. Toyota Motor -5,7 4,4 -3,2 
2. Roche 9,4 19,4 25 
3. Microsoft -3,3 13,9 38,6 
4. Volkswagen -2,3 5,7 2,4 
5. Pfizer -2,4 15,5 21,3 
6. Novartis 2,5 16,7 23,2 
7. Nokia -6,1 12,2 2,8 
8. Johnson&Johnson 7,8 11,3 26 
9.Sanofi-Aventis 0,3 15,3 24,6 
10. Samsung Electronics 8 5,4 9,3 
11. Siemens 1,9 5,6 4,9 
12. General Motors -24,1 5,3 -7,7 
13. Honda Motor -4,2 5,6 1,4 
14. Daimler -6,2 5,3 -0,3 
15. GlaxoSmithKline 9,5 12,8 26,8 
16. Merck 21,6 21,3 56,6 
17. Intel -1,2 16,1 15,6 
18. Panasonic -6,6 6,7 -5 
19. Sony -4,5 6,5 -3 
20. Cisco Systems 1,1 14,4 19,9 
21. Robert Bosch -8,6 9,4 -3 
22. IBM -9,9 5,2 19,1 
23. Ford Motor -32,9 4,1 2,6 
24. Nissan Motor -0,4 5,4 -3,1 
25.Takeda Pharmaceutical 64,3 29,5 20,3 
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26. Hitachi -2,7 4,2 -1,8 
27. AstraZeneca -12 13,5 34,6 
28, Eli Lilly 12,6 19,8 25,3 
29. Bayer  8,8 9,5 9 
30 EADS 4,4 6,7 -1,1 
31. Toshiba  -3,8 5,7 -5 
32. Alcatel-Lucent -14,3 17,9 -5,8 
33. NEC -1,6 8,2 -6,3 
34. Bristol-Mayers 1,7 16,9 29,8 
35.BMV -14,5 5,1 0,5 
36. Boeing 0,9 5,1 3,1 
37. Ericsson -12,1 11,9 2,4 
38. General Electric 10,1 2,1 18 
39. Peugeot -2,4 4,8 -2,8 
40. Canon -18,6 9,5 7 
41. Oracle 17,6 12,1 33,6 
42. Denso -4,6 9,5 -2,5 
43. Motorola -22,5 14,4 -0,2 
44. Boehringer Ingelheim 5 17,4 17,7 
45. NTT -1,1 2,6 10,9 
46. Amgen -5,5 19,6 37,6 
47. Google 1,8 12 35,2 
48. Hewlett-Packard -20,4 2,5 8,8 
49. Finmeccanica 9,9 11,7 7 
50.Abbott Laboratories 2 8,9 24,7 
Source: European Commission (2010). 
Research and development activity remains strongly concentrated in 
enterprises that earmark a lot of money for R&D expenditures (10 leading 
innovative enterprises accounted for 13.6% of total expenditures on R&D 
among 1400 analysed companies).  
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In the group of 50 companies with the biggest R&D expenditures 30 
enterprises reduced their investment in this activity (among which 15 companies 
by more than 5%). In the following companies a double-digit reduction of R&D 
expenditures was noted: Ford Motor (by 32.9%), General Motor (24.1%), 
Motorola (2.5%), Hewlett-Packard (20.4%), Canon (18.6%), BMW (14.5%), 
Alcatel-Lucent (14.3%), Ericsson (12.1) and AstraZeneca (12%). Among 
remaining 20 companies that noted the rise of R&D expenditures 9 enterprises 
increased this investment by more than 5%. Double-digit rise of research and 
development expenditures was observed in the following companies: Takeda 
Pharmaceuticals (64.3%), Merck (21.6%), Oracle (17.6%), Eli Lilly (12.6) and 
General Electric (10.1%).  
In the whole group of enterprises increasing R&D expenditures we can 
find not only companies achieving good financial results (i.e. net sales or 
operating profit value) such as Huawei Technologies (increase of R&D 
expenditures by 27.8%), Apple (25.4%), Oracle (17.6%), but also companies 
experiencing a significant decrease of sales and profits: Bayer (8.8%,) General 
Electric (10.1%) or Daiichi Sankyo (12.9%). In the case of the latter company 
the decrease of profits in 2010 in relation to year 2009 amounted to 294% 
[European Commission (2010)]. 
4. Reaction of innovative companies to crisis – sectoral aspects 
Research and development expenditures in the group of analysed 
enterprises are characterised by strong concentration in the cross section of 
economic sectors. Three among sectors of so-called ICB - Industry 
Classification Benchmark: Pharmaceuticals & Biotechnology, Technology 
Hardware & Equipment, Automobiles&Parts in 2009 accounted for 51.7% of 
total investments in R&D among 1400 innovative enterprises, whereas 15 
leading innovative sectors accounted for 92% of total investments in R&D.  
In this paper the notion: innovative sectors is used to describe the sectors in 
which we find enterprises with the biggest share of total R&D expenditures of 
1400 analysed enterprises. 
Among 50 companies with particularly high R&D expenditures in 2009 
35 enterprises belonged to three sectors: Pharmaceuticals & Biotechnology, 
Automobiles & Parts and Technology Hardware & Equipment (compare tab. 2), 
which confirms a strong concentration of research and development 
expenditures in cross-section of economic sectors.  
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Table 2. Leading innovative enterprises (50) by economic sectors  
Sector Total 
Pharmaceuticals&Biotechnology 14 
Automobiles&parts 11 
Technology Hardware&Equipment 10 
Software&Computer Services 4 
Aerospace&defence 4 
Leisure goods 3 
Electronic&Electrical Equipment 2 
Chemicals 1 
Industrial Engineering 1 
Source: European Commission (2010). 
The best results in the field of R&D expenditures were achieved by 
Pharmaceuticals & Biotechnology sector and it was placed in No 1 position in 
the ranking of the most innovative sectors. R&D expenditures in this sector 
accounted for 19% of R&D investments observed in 1400 leading innovative 
enterprises. Research and development expenditures in Pharmaceuticals & 
Biotechnology sector in the group of analysed enterprises rose in relation to the 
previous year by 5.3% (compare tab. 3). Simultaneously, it is one of very few 
sectors that managed to increase net sales in the time of crisis (by 6.4% in 
relation to year 2008)3. To a great extent the strengthening of research and 
development ability was achieved by processes of economic concentration4. 
Pharmaceuticals&Biotechnology sector is also the sector characterised by the 
biggest intensity of research and development expenditures in 2009 (i.e. the 
relation of research and development expenditures to net sales). 
No 2 position in the ranking of the most innovative sectors was occupied 
by Technology Hardware&Equipment sector which in 2009 accounted for 
17.2% of total investments in R&D of 1400 innovative enterprises. However, 
this sector turned out to be little resistant to crisis – research and development 
expenditures of this sector in the group of analysed enterprises fell in relation to 
the previous year by 6.4%.  
                                                 
3
 European Commission (2010). 
4
 p. Roche acquired Genentch, Pfizer acquired Wyeth, Sanofi-Aventis acquired Zentiva 
[IMMA (2009), Mergers and Acquisitions Report]. 
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Automobiles & Parts sector proved to be even less resistant to crisis. Even 
though it is still one of the most innovative sectors (in the ranking of leading 
innovative sectors it held no 3 position in 2009 and accounted for 15.6% of total 
investments in R&D in analysed enterprises), it was this very sector in which the 
biggest decrease in R&D expenditures (by 11.6%) was observed. 
Automotive industry that belongs to medium-tech industries was one of 
the first to suffer from an economic crisis in the area of sales, company value 
and profit. Among 12 global car manufacturers it was only Hyundai Motors that 
increased research and development expenditures by 2% in 2009. 
Table 3. Changes of expenditures in innovative enterprises and the value of R&D intensity 
index by economic sectors  
Sector R&D Investment (change 
09/08, %) 
R&D 
intensity, % 
1. Pharmaceuticals&Biotechnology 5,3 15,9 
2. Technology Hardware&Equipment -6,4 6,6 
3. Automobiles&parts -11,6 4,7 
4. Software&Computer Services -0,1 9,9 
5.Electronic&Electrical Equipment 1,1 4,4 
6. Chemicals 2,7 3,4 
7. Aerospace&defence -1 3,9 
8. Leisure goods -4,8 6,5 
9. Automobiles&parts -1,8 3,1 
10. Industrial Engineering -1,8 2,6 
11. Fixed line telecommunications 1,3 1,7 
12. Health care equipment&services 5,1 6,2 
13. Oil&gas production 2,6 0,4 
14. Food producers 0,8 1,2 
All sectors -1,9 3,5 
Source: European Commission (2010). 
Some sectors noted an increase of research and development expenditures 
in spite of a significant fall of net sales (Chemicals, Oil & Gas Production). 
Research and development expenditures in Chemicals sector in the group of 
1400 analysed enterprises increased in relation to the previous year by 2.7% and 
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Oil & Gas Production by 2.6 % (net sales value fell respectively by 26% and 
16.1%). The increase of R&D expenditures in Health care equipment & services 
sector is also an example of a positive, anti-cyclical reaction to crisis. 
4. Reaction of innovative companies to crisis – geographical aspects 
The factor differentiating the changes in research and development 
strategies of innovative companies in their response to crisis is their 
geographical location.  
1400 enterprises analysed in the cited report which were classified on the 
basis of their research and development expenditures can be divided on the 
ground of their geographical location into two group: 400 leading enterprises 
from the EU, 504 from the USA (27 less than the previous year ranking), 259 
from Japan (3 more than in the 2008 ranking) and 237 business entities from 
other countries (24 more than in the previous year). 
In 2009 American enterprises accounted for 34.3% of total investments in 
R&D among 1400 innovative enterprises, whereas enterprises from the EU for 
30.6% (compare graph 2). 
Figure 2. Research and development expenditures of leading innovative enterprises by  
the most important regions of the world in 2009 
 
 
 
 
 
 
 
 
 
 
Source: European Commission (2010). 
USA
(34,30%)
EU
(30,60%)
Japan
(22,00%)
Other
Countries
(13,10%)
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The share of American companies in total R&D expenditures of 1400 
leading innovative enterprises decreased significantly – from 37.7% in 2008 to 
34.3%, whereas the share of the EU enterprises increased by 1.7 percentage 
points. Japanese companies maintained their share in research and development 
investments in the analysed companies on the same level. However, the 
enterprises from other parts of the world increased their share in total research 
and development expenditures of 1400 leading innovative enterprises by 1.9 
percentage points. 
The companies that turned out to be the least resistant to crisis were the 
companies from the USA which reduced R&D expenditures by 5.1% in relation 
to the previous year. The enterprises from the EU that reported a fall in sales 
similar to American companies but a bigger fall in profits reduced R&D 
investments by 2.6%. Japanese companies in spite of a significant fall in net 
sales (by 10%) and a dramatic fall in profits (by 88.2%) managed to maintain 
research and development expenditures on the same level. However, the 
companies from other parts of the world increased research and development 
expenditures by 5.8% despite a fall in sales by 4.8% and a fall in profits by 
12.4%.  
The companies whose research and development activity proved to be 
exceptionally resistant to crisis were the enterprises from other Asian countries – 
innovative companies from this region increased research and development 
expenditures by 11% and at the same time their net sales rose by 5%. The 
highest dynamism of research and development expenditures was observed in 
enterprises from China (40%), India (27.3%), Hong Kong (14.8%), South Korea 
(9.1%) and Taiwan (3.1%).  
Pro-cyclical reaction of Asian enterprises to crisis is also confirmed by the 
fact that new companies from this region appeared in the ranking of the most 
innovative companies in the world. As it was already mentioned the ranking 
from 2009 included also three Japanese companies, six companies from China, 
four from Taiwan, four from South Korea, two from Hong Kong and two from 
Singapore. 
The crisis has not changed sectoral specialisation of the regions. 
Enterprises from the USA dominate in sectors producing high-tech goods, 
whereas companies from the EU in sectors producing medium-low tech goods. 
69% of research and development expenditures in American companies in 2009 
went to high-tech sectors, and 25% to medium-low-tech sectors. However, 
“only” 35% of research and development expenditures in the European 
innovative companies went to high-tech sectors and 48% to medium-high 
technology sectors. 
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5. Conclusions 
In the economic literature we can find arguments in favour of cyclical as 
well as anti-cyclical enterprises’ reactions to economic crisis. 
In the analysed period 1400 leading innovative enterprises reduced to  
a greater extent net sales and profits than research and development 
expenditures, which supports an anti-cyclical reaction of innovative companies 
to crisis. Some companies increased research and development expenditures in 
spite of worse economic results. However, some analysed companies reduced 
research and development expenditures, which confirms differentiating  
a research and development strategy as a reaction to crisis.  
The impact of crisis on corporate research and development activity 
depends on an economy sector. Among analysed companies the most resistant to 
crisis were the enterprises belonging to Pharmaceuticals & Biotechnology (high-
tech sector) and the most susceptible were the enterprises from Automobiles & 
Parts sector (medium technology). On the other hand reduction in research and 
development expenditures was noted also in Technology Hardware & 
Equipment sector that belongs to high technologies. However, the hypothesis 
that high–tech industries are more resistant to crisis is not supported -in a group 
of sectors that showed a cyclical reaction to crisis we find both high-tech and 
medium-tech sectors. 
The reaction of innovative companies to crisis was determined also by 
their geographical location. American companies as well as those from the EU 
in response to crisis reduced research and development expenditures, whereas 
Japanese companies maintained them on the unchanged level. Research and 
development activity in companies from the other geographical regions was 
definitely anti-cyclical (particularly the Asian companies). 
It must be noted, however, that analysed enterprises represent a sector of 
big enterprises which possess a large budget for research and development, thus 
their reaction to crisis is different than the reaction of less innovative companies.  
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Streszczenie 
 
NAKŁADY NA BADANIA I ROZWÓJ PRZEDSIĘBIORSTW 
INNOWACYJNYCH W DOBIE KRYZYSU 
 
W opracowaniu zbadano reakcję firm charakteryzujących się największymi 
nakładami na B+R w skali świata na aktualny kryzys. Celem analizy była odpowiedź na 
pytanie, jak wrażliwa na kryzys okazała się zmiana nakładów na badania i rozwój 
przedsiębiorstw innowacyjnych w porównaniu ze zmianami sprzedaży i zysków oraz,  
w jaki sposób charakter sektora i pochodzenie geograficzne przedsiębiorstw wpływa na 
zmiany ich nakładów badawczo-rozwojowych.  
Analizowane przedsiębiorstwa w większym stopniu ograniczyły sprzedaż netto 
oraz zyski, niż nakłady na badania i rozwój, co potwierdza względną odporność firm 
innowacyjnych na kryzys. Co prawda w badanej próbie część przedsiębiorstw znacząco 
zmniejszyła nakłady na badania i rozwój, jednakże niektóre firmy zanotowały wzrost 
nakładów na B+R, mimo pogorszenia wyników ekonomicznych. 
Wśród badanych sektorów najbardziej odpornym na kryzys okazał się, zaliczany 
do wysokich technologii, sektor Pharmaceuticals&Biotechnology, natomiast szczególnie 
podatnym na kryzys sektor Automobiles&parts. Nie znajduje jednak potwierdzenia teza, 
że przemysły wysokiej techniki są bardziej odporne na kryzys – wydatki na badania  
i rozwój sektora: Technology Hardware&Equipment (zaliczanego do wysokiej techniki) 
w 2009 r. zmniejszyły się w stosunku do 2008 r. 
W badanej zbiorowości przedsiębiorstw najmniejszą „odporność” na kryzys 
wykazały firmy amerykańskie. Firmy wywodzące się z UE również zanotowały 
zmniejszenie nakładów na badania i rozwój, jednak tempo spadku nakładów badawczo-
rozwojowych było tu mniejsze niż w przypadku firm amerykańskich.  
 
